InvestorsHub Logo
Post# of 200739
Next 10
Followers 24
Posts 811
Boards Moderated 0
Alias Born 10/07/2018

Re: nybull29 post# 29937

Tuesday, 09/17/2019 8:03:24 PM

Tuesday, September 17, 2019 8:03:24 PM

Post# of 200739
Can you provide a link to their patent and what is covers ? I was referring to one they said they had before joining with Marty and now acquiring his.


Annihilare had the patent , Marty joined PCT , now resigned and sold all rights to the patents to pct for 2,250,000 shares of PCTL


On July 30, 2019, the Company accepted a settlement proposal fromAnnihilare, Inc. (a sub-registrant of the Company’s US EPA Registration No. 92108-1) and its affiliated company, Prime ITS (a prior owner of Annihilyzer Inc, which transferred previously noted intangible IT assets to PCT LTD for 2,250,000 shares of the Company’s common stock in November of 2016). The settlement agreement included credit to the Company by Prime ITS in the gross amount of $23,209 on the Company’s payable to Prime ITS for a combination of a portion of Marty Paris’ salary, a resignation from Marty Paris effective July 31, 2019, and equal valued amount of PCT’s inventory, for net credit to PCT in the amount of $13,939, which was received by the Company on July 31, 2019. The transaction was completed on August 1, 2019.
On August 8, 2019, the Company received notice from PRIME ITS that certain technology services utilized by the Company shall cease to be provided, effective September 8, 2019. The Company will obtain competitive quotes from other technology services providers.
On August 8, 2019, the Company received notice fromAnnihilare, Inc. that certain intellectual properties developed jointly between the Company and Annihilare are to be discontinued from use by the Company and its customers. The Company disputes the claims fromAnnihilare that the intellectual properties are exclusively Annihilare’s and are in discussions with Annihilare on this point. Until this issue is resolved, the impact to the Company is minimal because the Company’s healthcare customers primarily benefit from the disinfecting fluid solutions utilized by deploying the Company’s Annihilyzer Infection Control System, along with the Company-owned, patent-protected RFID disinfectant/material tracking system. The disputed issue is relative to a protocol software system, which is not a necessary feature of the Company’s Annihilyzer Infection Control System. The protocol software system is considered a complimentary feature and the Company expended employee time and expertise in its development.